MedTrace Logo

The Effects of DHA on Attention Deficit and Hyperactivity Disorder

NCT01796262 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-02-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether docosahexaenoic acid (DHA) is effective in reducing Attention Deficit/Hyperactivity Disorder (ADHD) core symptoms in a clinical sample of children and adolescents with ADHD.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DIETARY_SUPPLEMENT

docosahexaenoic acid

Supplementation with DHA Richoil 250mg pearl b.i.d. for six months

DIETARY_SUPPLEMENT

Wheat germ oil

Wheat germ oil 250 mg pearl b.i.d. for six months

Sponsors & Collaborators

  • DMF srl (Dietetic Metabolic Food)

    collaborator UNKNOWN

  • IRCCS Eugenio Medea

    lead OTHER

Principal Investigators

  • Maria Nobile, MD, PhD · IRCCS 'Eugenio Medea'

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-02-28
Completion
2015-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796262 on ClinicalTrials.gov